Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation

Area of Science:

• Immunology
• Nephrology
• Transplantation Medicine

Background:

• m-TOR inhibitors like sirolimus are crucial for preventing organ rejection in renal transplantation.
• These immunosuppressants are linked to improved long-term graft survival.
• Early initiation of sirolimus is common but may lead to side effects such as impaired wound healing and delayed graft function.

Purpose of the Study:

• To provide evidence-based recommendations for managing sirolimus-related side effects in renal transplant recipients.
• To offer guidance on the optimal use of sirolimus during and after kidney transplantation surgery.
• To leverage clinical experience and published literature for practical management strategies.

Main Methods:

• Review of published literature on sirolimus use in renal transplantation.
• Consensus recommendations developed from the clinical experience of transplant clinicians.
• Guidance formulation for perioperative and postoperative sirolimus management.

Main Results:

• Sirolimus is associated with significant benefits in renal graft survival.
• Potential side effects include impaired wound healing, lymphoceles, and delayed graft function.
• Tailored clinical management strategies can effectively mitigate these adverse events.

Conclusions:

• Sirolimus is a valuable immunosuppressant in renal transplantation, offering long-term graft survival benefits.
• Proactive and individualized patient management is key to minimizing sirolimus-associated complications.
• Specific guidance for surgical settings can optimize sirolimus therapy and patient safety.